Keywords: AstraZeneca, Crestor, CV indication, Seroquel, Schizophrenia, Marketing practices, USA, EU
AstraZeneca gets new indication for Crestor in EU to prevent major CV events; agrees to pay $520 million to settle US Seroquel marketing case
Article | 27 April 2010
Anglo-Swedish drug major AstraZeneca’s cholesterol lowerer Crestor (rosuvastatin) has been approved in 19 countries within the European Union for the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
